

Thymus Chemokine 11/CXCL7

Catalog # PVGS1468

Product Information

Primary Accession Q99ME0
Species Rat

Sequence Ile46-Ile107

Purity > 97% as analyzed by SDS-PAGE

> 97% as analyzed by HPLC

Endotoxin Level

Biological Activity The EC₅₀ value of rat Thymus Chemokine 11/CXCL7 on Ca²⁺ mobilization assay

in CHO-K1/Gα15/rCXCR2 cells (human Gα15 and rat CXCR2 stably expressed

in CHO-K1 cells) is less than 300.0 ng/ml.

Expression System CHO

Formulation Lyophilized after extensive dialysis against PBS.

Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to

bring the contents to the bottom. Reconstitute the lyophilized powder in

ddH₂O or PBS up to 100 □g/ml.

Storage & Stability Upon receiving, this product remains stable for up to 6 months at lower than

-70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw

cycles.

Additional Information

Target Background

Thymus Chemokine \square 1, also called Chemokine (C-X-C motif) ligand 7 (CXCL7), is a member of the CXC chemokines. Similar to other ELR domain containing CXC chemokines such as IL-8 and the GRO proteins, Thymus Chemokine \square 1 has been shown to bind CXCR-2 and be a chemoattractant forneutrophils and play a role in their activation. Although CTAP-III, β -TG and PBP represent amino-terminal extended variants of Thymus Chemokine \square 1 and possess the same CXC chemokine domains, these proteins do not exhibit Thymus Chemokine \square 1 activity. Recently, it has been shown that the additional amino-terminal residues of CTAP-III mask the critical ELR receptor binding domain that is exposed on Thymus Chemokine \square 1 and may account for lack of Thymus Chemokine \square 1 activity. Rat CXCL7 shares 72% amino acid sequence identity with mouse CXCL7.

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.